CN110193052B

CN110193052B - Anti-inflammatory composition, anti-inflammatory product prepared from anti-inflammatory composition and application of anti-inflammatory product

Info

Publication number: CN110193052B
Application number: CN201910562586.3A
Authority: CN
Inventors: 王利利; 于晓霞; 欧阳小茜; 魏毅凡; 古润金
Original assignee: Yangzhou Perfect Commodity Co ltd; Perfect China Co Ltd; Perfect Guangdong Commodity Co Ltd
Current assignee: Yangzhou Perfect Commodity Co ltd; Perfect China Co Ltd; Perfect Guangdong Commodity Co Ltd
Priority date: 2019-06-26
Filing date: 2019-06-26
Publication date: 2022-06-03
Anticipated expiration: 2039-06-26
Also published as: CN110193052A

Abstract

The invention belongs to the field of daily cosmetics, and particularly relates to an anti-inflammatory composition, an anti-inflammatory product prepared from the anti-inflammatory composition and application of the anti-inflammatory composition. The anti-inflammatory composition comprises aloe extract, chamomile flower extract, dipotassium glycyrrhizinate and additives; the additive comprises at least one of dibenzoylmethane, a dibenzoylmethane derivative, or an isothiocyanate. The anti-inflammatory composition can prevent and treat skin inflammation, and has the advantages of simple formula, low cost and no toxic or harmful effect on human bodies.

Description

Anti-inflammatory composition, anti-inflammatory product prepared from anti-inflammatory composition and application of anti-inflammatory product

Technical Field

The invention belongs to the field of daily cosmetics, and particularly relates to an anti-inflammatory composition, an anti-inflammatory product prepared from the anti-inflammatory composition and application of the anti-inflammatory composition.

Background

At present, the serious air pollution condition generally exists in China, and the haze, the toxic dust particles and other pollutants in the air can cause damage to the skin of a human body, and cause symptoms such as inflammation, allergy and the like. Toxic contaminants can accumulate over prolonged exposure to the touch, can cause chronic pathological changes in the skin, and even lead to the development of tumors. Therefore, the skin health care product for resisting the toxic air pollutants is developed, can neutralize and reduce or eliminate the damage of the air pollutants to the skin, eliminate symptoms such as inflammation allergy and the like, prevent the generation of chronic skin pathological changes and prevent tumors and other chronic skin diseases.

Aloe is a perennial fleshy herb of Liliaceae, which contains barbaloin, aloe polysaccharide, etc. having various effects on the human body, and is widely used in the food, pharmaceutical and cosmetic industries. The aloe vera extract can relieve skin discomfort, maintain skin health, prevent skin roughness, enhance skin elasticity, and is non-irritating to the skin. Has adjuvant effect on incised wound, abrasion, wound ulceration, scald, skin itching, acne, black speck, mosquito bite, toothache, lip angle ulceration, operation scar, etc., and has antiinflammatory, antibacterial, hemostatic, analgesic, repercussive, antipruritic, rehabilitation, regeneration, antiallergic, wound healing accelerating, and scar reducing effects. Although the aloe extract has a great number of efficacies, the efficacy is not remarkable enough, so that other functional components are generally added for enhancing the effects of whitening, removing acnes, resisting aging, resisting inflammation and the like. For example: chinese patent application CN102552642A discloses a medicament for treating acne in young people and having whitening effect, comprising: dried flos persicae, radix Angelicae Dahuricae, Poria, semen Benincasae, semen Armeniacae amarum, fresh Aloe gel, Mel, pure glycerol, pure milk and vanishing cream; has effects in removing skin dirt, clearing away heat, relieving pain, relieving itching, relieving inflammation, removing toxic materials, improving local blood circulation, promoting cell regeneration, softening skin stratum corneum, astringing, keeping moisture, and nourishing skin. However, the medicine has complex components, is not beneficial to quality control, and is added with a large amount of food-borne substances, thereby having slow effect and high cost.

Dibenzoylmethane (DBM) and derivatives thereof are common ultraviolet absorbers, and the structures of the compounds have a long conjugated system, so that the compounds have a good absorption effect on long-wave ultraviolet rays and are harmless to human bodies, and the compounds are generally used as sun-screening additives in the field of daily chemicals. Isothiocyanate (ITC) is a compound with the general formula of R-N-C-S, a large amount of glucosinolate, called glucosinolate for short, exists in roots, stems, leaves and seed cells of cruciferous plants such as cauliflower, cabbage, mustard, radish and the like, and the glucosinolate reacts with glucosinolase to generate Isothiocyanate; isothiocyanate has active chemical property, has various special physiological activities, such as inhibiting cancer cell and tumor growth, sterilizing and resisting platelet aggregation, and can remarkably reduce the risk of suffering from renal, prostate, bladder, colon, rectum and lung cancer. However, there is no report of the use of dibenzoylmethane and its derivatives and isothiocyanates for skin inflammation, nor is there any technique for combining it with aloe vera extract for anti-inflammation.

Disclosure of Invention

Therefore, the technical problem to be solved by the invention is to overcome the defect that the aloe extract and the dibenzoylmethane and the derivatives thereof or the isothiocyanate are not combined for treating skin inflammation in the prior art, so that the composition with simple composition, low cost and good anti-inflammatory effect, the anti-inflammatory product prepared from the composition, and the preparation method and the application of the composition are provided.

Therefore, the technical scheme of the invention is as follows:

an anti-inflammatory composition comprises Aloe extract, flos Matricariae Chamomillae extract, dipotassium glycyrrhizinate and additives;

the additive comprises at least one of dibenzoylmethane, a dibenzoylmethane derivative, or an isothiocyanate.

Preferably, the aloe extract food comprises, by weight, 0.05-1 part of aloe extract, 1-5 parts of chamomile extract, 0.05-2.5 parts of dipotassium glycyrrhizinate and 0.1-10 parts of additives.

Preferably, the addition amount of the aloe extract is 0.05-0.5 parts by weight.

Preferably, the additive comprises 0.1 to 5 parts of dibenzoylmethane or dibenzoylmethane derivative, and/or 0.5 to 5 parts of isothiocyanate.

Preferably, the isothiocyanate is one selected from the group consisting of benzyl isothiocyanate, phenethyl isothiocyanate, phenyl isothiocyanate and allyl isothiocyanate.

Preferably, the dibenzoylmethane derivative is butyl methoxydibenzoylmethane.

The invention also provides a preparation method of the anti-inflammatory composition, which comprises the steps of dissolving the additive by using an organic solvent, and uniformly mixing the additive with the aloe extract, the chamomile flower extract and the dipotassium glycyrrhizinate.

Preferably, the organic solvent is ethanol. Preferably, the amount of the organic solvent is 1-50% of the mass of the additive.

The invention also provides an anti-inflammatory product, which comprises the anti-inflammatory composition and auxiliary materials.

Preferably, the auxiliary materials comprise one or more of a humectant, a thickener, an emulsifier, a gel, a preservative, an antioxidant, a soothing agent, a skin conditioner, an acid-base regulator, an emollient, a chelating agent, an essence and water.

Preferably, the humectant is selected from one or more of glycerin, propylene glycol, 1, 3-butanediol, methyl propylene glycol and sodium hyaluronate;

the thickening agent is selected from one or more of acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer, carbomer, xanthan gum, hydroxyethyl cellulose, hydroxypropyl cellulose and hydroxypropyl methyl cellulose;

the emulsifier is one or more selected from sucrose stearate, cetyl palmitate, polyglycerol-3 methyl glucose distearate, PEG-20 behenate, sorbitan olivate, cetearyl olivate, polyglycerol-6 stearate, glyceryl stearate, polyglycerol-6 behenate, steareth-21 and PEG-100 stearate;

the alkaline regulator is selected from one or more of sodium hydroxide, triethanolamine and arginine;

the soothing agent is one or more selected from chamomile extract and alpha-bisabolol.

Preferably, the anti-inflammatory product comprises an anti-inflammatory drug, an anti-inflammatory cosmetic, and an anti-inflammatory daily product.

The invention also provides a preparation method of the anti-inflammatory product, which is prepared by mixing the anti-inflammatory composition and the auxiliary materials according to a conventional process.

The invention also provides application of the anti-inflammatory composition in preparation of medicines and daily chemicals with anti-inflammatory effects.

In the present invention, the aloe extract is prepared by the following method:

selecting mature aloe leaves with more than three years of growth period, cleaning with clear water, draining off water, removing epidermis, and mechanically pulping under aseptic condition to obtain pulp; then adding purified water for dilution, performing centrifugal separation, and removing residues to obtain colloidal extract; and (3) drying and spraying the colloidal extract at a low temperature after freezing and dehydrating, drying at a low temperature of 60 ℃ until the water content is 8%, taking out, cooling to a normal temperature state, and sieving by a 100-200-mesh sieve to obtain the aloe extract.

The technical scheme of the invention has the following advantages:

1. the invention provides an anti-inflammatory composition, which comprises aloe extract, chamomile extract, dipotassium glycyrrhizinate and additive; the additive comprises at least one of dibenzoylmethane, a dibenzoylmethane derivative, or an isothiocyanate. According to the invention, the dibenzoylmethane and/or dibenzoylmethane derivatives and/or isothiocyanates are used for treating skin inflammation for the first time, a certain anti-inflammatory effect is found, and after the dibenzoylmethane and/or dibenzoylmethane derivatives and/or isothiocyanates are mixed with the aloe extract, the dibenzoylmethane and the aloe extract have an obvious synergistic effect and an obvious anti-inflammatory effect. The anti-inflammatory composition provided by the invention is simple in formula, low in cost, simple in preparation method and free of toxic and harmful effects on human bodies.

2. The anti-inflammatory composition provided by the invention comprises, by weight, 0.05-1 part of aloe extract, 1-5 parts of chamomile extract, 0.05-2.5 parts of dipotassium glycyrrhizinate and 0.1-10 parts of additive. Further, the additive comprises 0.1-5 parts of dibenzoylmethane or dibenzoylmethane derivative and/or 0.5-5 parts of isothiocyanate. Under the specific dosage, the aloe extract, the chamomile flower extract, the dipotassium glycyrrhizinate and the additive with the specific dosage are matched with each other, so that the anti-inflammatory effect of the composition is further improved.

3. The invention provides an anti-inflammatory product, which is characterized in that the anti-inflammatory composition disclosed by the invention is matched with auxiliary materials, so that the anti-inflammatory composition can be used for preventing and treating skin inflammation, the skin nutrition requirement in daily life can be ensured, the effects of skin moisture preservation, wrinkle resistance, anti-inflammation and the like can be realized without being matched with other skin care products, and the moistening and nourishing effects are achieved.

Drawings

FIG. 1 shows the degree of improvement of skin inflammation of mouse ears by different substances;

FIG. 2 shows mouse ear tissue sections, (A) shows mouse ear tissue sections of a model group, and (B) shows mouse ear tissue sections of an experimental group C;

FIG. 3 shows the degree of improvement of the skin inflammation of the mouse ear by different substances;

FIG. 4 shows the degree of effect of different substances on the mouse ear skin inflammatory factor IL-6;

FIG. 5 shows the degree of effect of different substances on MIP-2, a mouse ear skin inflammatory factor;

FIG. 6 shows the degree of effect of different substances on the inflammatory factor TIMP-1 in the skin of the mouse ear.

Detailed Description

The technical solutions of the present invention will be described clearly and completely below, and it is obvious that the described embodiments are some, not all embodiments of the present invention, and all other embodiments obtained by those skilled in the art without creative efforts based on the embodiments of the present invention belong to the protection scope of the present invention. Furthermore, the technical features mentioned in the different embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other; unless otherwise indicated, the experimental procedures disclosed in the present invention are performed by conventional techniques in the art, and the reagents and starting materials used in the examples are commercially available. The chamomile extract of the following examples is of the type Camomile Distillate SB/NA22033, available from Poa Dahly Chemicals (Shanghai).

Example 1

An antiinflammatory composition comprises Aloe extract 0.06mg, flos Matricariae Chamomillae extract 1.5mg, dipotassium glycyrrhizinate 0.09mg and dibenzoyl methane 1.12 mg.

The preparation method of the anti-inflammatory composition comprises the following steps:

dissolving dibenzoyl methane in 0.56mg ethanol, and mixing with Aloe extract, flos Matricariae Chamomillae extract, and dipotassium glycyrrhizinate.

Example 2

An antiinflammatory composition comprises Aloe extract 0.06mg, flos Matricariae Chamomillae extract 1.5mg, dipotassium glycyrrhizinate 0.09mg and dibenzoyl methane 0.45 mg.

dissolving dibenzoyl methane in 0.18mg ethanol, and mixing with Aloe extract, flos Matricariae Chamomillae extract, and dipotassium glycyrrhizinate.

Example 3

An antiinflammatory composition comprises Aloe extract 0.05mg, flos Matricariae Chamomillae extract 5mg, dipotassium glycyrrhizinate 0.05mg and butyl methoxy dibenzoylmethane 0.1 mg.

dissolving butyl methoxy dibenzoyl methane in 0.05mg ethanol, and mixing with Aloe extract, flos Matricariae Chamomillae extract, and dipotassium glycyrrhizinate.

Example 4

An antiinflammatory composition comprises Aloe extract 1mg, flos Matricariae Chamomillae extract 1mg, dipotassium glycyrrhizinate 2.5mg and dibenzoylmethane 5 mg.

dissolving dibenzoylmethane in 0.5mg ethanol, and mixing with Aloe extract, flos Matricariae Chamomillae extract, and dipotassium glycyrrhizinate.

Example 5

An antiinflammatory composition comprises Aloe extract 0.06mg, flos Matricariae Chamomillae extract 1.5mg, dipotassium glycyrrhizinate 0.09mg and phenethyl isothiocyanate 0.5 mg.

dissolving phenethyl isothiocyanate with 0.1mg ethanol, and mixing with Aloe extract, flos Matricariae Chamomillae extract, and dipotassium glycyrrhizinate.

Example 6

An antiinflammatory composition comprises Aloe extract 0.06mg, flos Matricariae Chamomillae extract 1.5mg, dipotassium glycyrrhizinate 0.09mg and phenethyl isothiocyanate 1.5 mg.

dissolving phenethyl isothiocyanate with 0.5mg ethanol, and mixing with Aloe extract, flos Matricariae Chamomillae extract, and dipotassium glycyrrhizinate.

Example 7

An anti-inflammatory composition comprises aloe extract 0.5mg, flos Matricariae Chamomillae extract 1.8mg, dipotassium glycyrrhizinate 1mg and benzyl isothiocyanate 0.5 mg.

dissolving benzyl isothiocyanate with 0.2mg ethanol, and mixing with Aloe extract, flos Matricariae Chamomillae extract, and dipotassium glycyrrhizinate.

Example 8

An antiinflammatory composition comprises Aloe extract 0.5mg, flos Matricariae Chamomillae extract 1.8mg, dipotassium glycyrrhizinate 1mg and phenyl isothiocyanate 5 mg.

dissolving phenyl isothiocyanate with 5mg ethanol, and mixing with Aloe extract, flos Matricariae Chamomillae extract, and dipotassium glycyrrhizinate.

Example 9

An anti-inflammatory composition comprises Aloe extract 0.1mg, flos Matricariae Chamomillae extract 1.5mg, dipotassium glycyrrhizinate 0.09mg, dibenzoylmethane 0.1mg and phenethyl isothiocyanate 4.5 mg.

dissolving dibenzoylmethane and phenethyl isothiocyanate in 1.8mg ethanol, and mixing with Aloe extract, flos Matricariae Chamomillae extract and dipotassium glycyrrhizinate.

Example 10

An anti-inflammatory composition comprises Aloe extract 0.5mg, flos Matricariae Chamomillae extract 3mg, dipotassium glycyrrhizinate 1.6mg, dibenzoylmethane 5mg and phenyl isothiocyanate 5 mg.

dissolving dibenzoylmethane and phenyl isothiocyanate in 10mg ethanol, and mixing with Aloe extract, flos Matricariae Chamomillae extract, and dipotassium glycyrrhizinate.

Example 11

An antiinflammatory product comprises Aloe extract 0.06mg, flos Matricariae Chamomillae extract 1.5mg, dipotassium glycyrrhizinate 0.09mg, dibenzoylmethane 1.12mg, carbomer 0.45mg, 1, 3-butanediol 3mg, sucrose stearate 0.5mg, triethanolamine 0.39mg, alpha-bisabolol 0.015mg, and deionized water 24.6 mg.

The preparation method of the anti-inflammatory product comprises the following steps:

dissolving dibenzoyl methane in 0.1mg ethanol, and mixing with Aloe extract, flos Matricariae Chamomillae extract, dipotassium glycyrrhizinate, carbomer, 1, 3-butanediol, sucrose stearate, triethanolamine, alpha-bisabolol, and deionized water.

Example 12

An antiinflammatory product comprises Aloe extract 0.06mg, flos Matricariae Chamomillae extract 1.5mg, dipotassium glycyrrhizinate 0.09mg, phenethyl isothiocyanate 0.735mg, hydroxyethyl cellulose 0.5mg, glycerol 2.1mg, sorbitan olivil oleate 0.3mg, sodium hydroxide 0.12mg, alpha-bisabolol 0.015mg, and deionized water 24.6 mg.

dissolving phenethyl isothiocyanate with 0.2mg ethanol, and mixing with Aloe extract, flos Matricariae Chamomillae extract, dipotassium glycyrrhizinate, hydroxyethyl cellulose, glycerol, sorbitan Olive oleate, sodium hydroxide, alpha-bisabolol, and deionized water.

Example 13

An antiinflammatory product comprises Aloe extract 0.2mg, flos Matricariae Chamomillae extract 1.9mg, dipotassium glycyrrhizinate 1.8mg, phenyl isothiocyanate 2.1mg, acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer 1.0mg, sodium hyaluronate 1.9mg, glyceryl stearate 0.6mg, sodium hydroxide 0.12mg, flos Matricariae Chamomillae extract 0.02mg, and deionized water 25.6 mg.

dissolving phenyl isothiocyanate with 0.8mg ethanol, and mixing with Aloe extract, flos Matricariae Chamomillae extract, dipotassium glycyrrhizinate, acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer, sodium hyaluronate, glyceryl stearate, sodium hydroxide, flos Matricariae Chamomillae extract, and deionized water.

Example 14

An antiinflammatory product comprises Aloe extract 0.2mg, flos Matricariae Chamomillae extract 1.9mg, dipotassium glycyrrhizinate 1.8mg, dibenzoylmethane 1.9mg, xanthan gum 1.0mg, propylene glycol 1.2mg, PEG-100 stearate 0.6mg, sodium hydroxide 0.12mg, flos Matricariae Chamomillae extract 0.02mg, and deionized water 25.6 mg.

dissolving dibenzoyl methane in 0.8mg ethanol, mixing with Aloe extract, flos Matricariae Chamomillae extract, dipotassium glycyrrhizinate, xanthan gum, propylene glycol, PEG-100 stearate, sodium hydroxide, flos Matricariae Chamomillae extract, and deionized water, and preparing by conventional method to obtain the antiinflammatory product.

Comparative example 1

An anti-inflammatory composition is prepared by dissolving 1.12mg dibenzoylmethane in 0.56mg ethanol.

Comparative example 2

An anti-inflammatory composition is prepared by dissolving 0.735mg phenethyl isothiocyanate in 0.2mg ethanol.

Comparative example 3

An antiinflammatory composition comprises Aloe extract 0.06mg, flos Matricariae Chamomillae extract 1.5mg, and dipotassium glycyrrhizinate 0.09 mg.

adding 0.56mg ethanol into Aloe extract, flos Matricariae Chamomillae extract, and dipotassium glycyrrhizinate, and mixing.

Experimental example 1

Molding: 25 female CD-1 mice were selected and randomly divided into 5 groups of 5 mice, each group consisting of a control group, a model group and experimental groups A-C. During molding, 1 mu L of acetone is adopted to dissolve 1.5nmol of phorbol fat and then the experimental part is smeared, and then TPA smearing is adopted, namely phorbol fat smearing dissolved by acetone is adopted. Control group: smearing with 1 μ L acetone for 10min, and smearing once again; model group: smearing with TPA for 10min, and smearing once again; experimental group a: smearing with TPA, then smearing with the composition prepared in comparative example 1, and smearing with TPA once after 10 min; experimental group B: smearing with TPA, then smearing with the composition prepared in comparative example 3, and smearing with TPA once after 10 min; experimental group C: smearing the composition prepared in example 1 with TPA, and smearing with TPA once after 10 min; the corresponding medicament is smeared on the ear experiment part of each mouse once a day for 4 days. On day four, 6 hours after application, the mouse ear was punched using a punch (6 mm diameter), and the ear tissue samples were taken and weighed, the ear weight representing the degree of inflammatory swelling. And collecting mouse ear samples of the model group and the experimental group, carrying out tissue fixation by formalin solution, embedding tissues by paraffin and preparing paraffin tissue sections. The obtained paraffin sections of mouse ears were stained with hematoxylin/eosin (H & E) and analyzed for pathological changes.

Fig. 1 shows the degree of improvement of the skin inflammation of the ear of a mouse by the different substances, and the inhibition ratio (%) (degree of swelling in model group-degree of swelling in administered group)/degree of swelling in model group × 100%, it can be seen that, compared with the model group, the experiment group a can inhibit the inflammation by about 23%, the experiment group B can inhibit the inflammation by about 9%, and the experiment group C can inhibit the inflammation by 51%. And the formula calculation shows that the aloe vera gel and the dibenzoyl methane have obvious synergistic effect.

The synergy is calculated according to the formula of gold:

q＝E(A+B)/[EA+EB-EA*EB]

in the formula, EA and EB have the effect when A and B are used independently; e (A + B) is the effect of the combination of the two.

q is 0.85-1.15 is simple addition; 1.15< q <20 for enhancement; q >20 is significant enhancement; q <0.56-0.85 is antagonistic; q <0.55 is clearly antagonistic.

FIG. 2 is a mouse ear tissue section, (A) is a model group mouse ear tissue section, and it can be seen that epidermal tissue in the mouse ear tissue section is thickened and contains a large amount of infiltrating inflammatory cells after molding with TPA; (B) as shown by the ear sections of the mice in the experimental group C, after the anti-inflammatory composition is smeared on the ears of the mice, the epidermal tissues recover to be thinner and normal, and the number of infiltrating inflammatory cells is greatly reduced.

Experimental example 2

Molding: 35 female CD-1 mice were selected and randomly divided into 7 groups of 5 mice, namely a control group, a model group and experimental groups 1-5. During molding, 1 mu L of acetone is adopted to dissolve 1.5nmol of phorbol fat and then the experimental part is smeared, and then TPA smearing is adopted, namely phorbol fat smearing dissolved by acetone is adopted. Blank control group: smearing with 1 μ L acetone for 10min, and smearing once again; model group: smearing with TPA for 10min, and smearing once again; experimental group 1: smearing with TPA, then smearing with the composition prepared in comparative example 3, and smearing with TPA once after 10 min; experimental group 2: smearing with TPA and then smearing with the composition prepared in example 2, and smearing with TPA once after 10 min; experimental group 3: smearing the composition prepared in example 1 with TPA, and smearing with TPA once after 10 min; experimental group 4: smearing the composition prepared in example 5 with TPA, and smearing the composition with TPA once after 10 min; experimental group 5: the composition prepared in example 6 was applied after application of TPA and applied once more with TPA after 10 min. The corresponding medicament is applied to the ear experiment part of each mouse once a day for 4 days. On day four, 6 hours after application, the mouse ear was punched using a punch (6 mm diameter), and the ear tissue samples were taken and weighed, the ear weight representing the degree of inflammatory swelling. The collected mouse ear samples were homogenized in a buffer, the homogenate was centrifuged, and the supernatant was collected and assayed for the levels of the cytokines IL-6, MIP-2 and TIMP-1 by ELISA. The inhibition ratio (%) was (degree of swelling in model group-degree of swelling in administered group)/degree of swelling in model group × 100%.

FIG. 3 shows the degree of improvement of skin inflammation of mouse ears by different substances; it can be seen that the model group successfully induced the inflammation of the skin of the ear of the mouse, and compared with the model group, the experiment group 1 can inhibit the inflammation by 6%, the experiment group 2 can inhibit the inflammation by 30%, the experiment group 3 can inhibit the inflammation by 52%, the experiment group 4 can inhibit the inflammation by 48%, and the experiment group 5 can inhibit the inflammation by 23%. It can be seen that the anti-inflammatory composition of the present application can significantly inhibit the inflammation of the skin ears of mice.

FIG. 4 shows the degree of effect of different substances on the mouse ear skin inflammatory factor IL-6; compared with a control group, the inflammatory factor of the model group is obviously increased; compared with the model group, the experimental group 1 can inhibit the IL-6 level by about 15%; the inhibition rates of experimental groups 2 and 3 to which dibenzoylmethane was added were 48% and 40%, respectively, for the IL-6 level; the inhibition rates of experimental groups 4 and 5 to which phenethyl isothiocyanate was added were 54% and 66%, respectively, for the IL-6 level. As can be seen, the anti-inflammatory composition of the present application can significantly reduce the level of the inflammatory factor IL-6.

FIG. 5 shows the degree of effect of different substances on MIP-2, a mouse ear skin inflammatory factor; compared with a control group, the inflammatory factor of the model group is obviously increased; compared with the model group, the experimental group 1 can inhibit the MIP-2 level by about 13%; the inhibition rates of experimental groups 2 and 3 with dibenzoylmethane added were 41% and 41% for the MIP-2 level, respectively; the inhibition rates of experimental groups 4 and 5 to which phenethyl isothiocyanate was added were 31% and 33% for the MIP-2 level, respectively. As can be seen, the anti-inflammatory composition of the present application can significantly reduce the level of the inflammatory factor MIP-2.

FIG. 6 shows the degree of effect of different substances on the inflammatory factor TIMP-1 of the mouse ear skin; compared with a control group, the inflammatory factor of the model group is obviously increased; compared with the model group, the experimental group 1 can inhibit the TIMP-1 at a level of about 12%; the inhibition rates of experimental groups 2 and 3 to the TIMP-1 level with dibenzoylmethane addition were 32% and 53%, respectively; the inhibition rates of experimental groups 4 and 5 to which phenethyl isothiocyanate was added were 47% and 21% for the TIMP-1 level, respectively. As can be seen, the anti-inflammatory compositions of the present application can significantly reduce the level of the inflammatory factor TIMP-1.

Experimental example 3

Molding: 35 female CD-1 mice were selected and randomly divided into 7 groups of 5 mice, namely a control group, a model group and experimental groups 1-5. During molding, 1 mu L of acetone is adopted to dissolve 1.5nmol of phorbol fat and then the experimental part is smeared, and then TPA smearing is adopted, namely phorbol fat smearing dissolved by acetone is adopted. Blank control group: smearing with 1 μ L acetone for 10min, and smearing once again; model group: smearing with TPA for 10min, and smearing once again; experimental group 1: smearing with TPA, smearing with the anti-inflammatory product prepared in comparative example 3, and smearing with TPA once after 10 min; experimental group 2: the anti-inflammatory product prepared in example 11 was applied after TPA application, and applied once with TPA after 10 min; experimental group 3: the anti-inflammatory product prepared in example 12 was applied after TPA application, and applied once with TPA after 10 min; experimental group 4: smearing with TPA, then smearing with the composition prepared in comparative example 1, and smearing with TPA once after 10 min; experimental group 5: the composition prepared in comparative example 2 was applied after TPA application and applied once more with TPA after 10 min. The corresponding medicament is applied to the ear experiment part of each mouse once a day for 4 days. On day four, 6 hours after application, the mouse ear was punched using a punch (6 mm diameter), and the ear tissue samples were taken and weighed, the ear weight representing the degree of inflammatory swelling. The inhibition ratio (%) was (degree of swelling in model group-degree of swelling in administration group)/degree of swelling in model group × 100%, and the results are shown in table 1.

TABLE 1 degree of improvement of mouse ear skin inflammation by different substances

Group of	Ear tissue sample weight mg	Rate of inflammation inhibition
			Control group	7.03±1.25	-
Model set	16.98±1.34	-
			Experimental group 1	15.36±1.21	9.54％
Experimental group 2	8.41±1.09	50.47％
			Experimental group 3	10.23±1.33	39.66％
Experimental group 4	13.14±1.42	22.51％
			Experimental group 5	15.19±1.18	10.58％

It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. This need not be, nor should it be exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.

Claims

1. An anti-inflammatory composition is characterized by comprising 0.05 to 1 portion of aloe extract, 1 to 5 portions of chamomile extract, 0.05 to 2.5 portions of dipotassium glycyrrhizinate and 0.1 to 10 portions of additive in portion by weight;

the additive comprises 0.1-5 parts of dibenzoyl methane or dibenzoyl methane derivative and/or 0.5-5 parts of isothiocyanate;

the isothiocyanate is selected from one of benzyl isothiocyanate, phenethyl isothiocyanate, phenyl isothiocyanate and allyl isothiocyanate;

the dibenzoylmethane derivative is butyl methoxydibenzoylmethane;

the aloe extract is prepared by the following method:

selecting mature aloe leaves with more than three years of growth period, cleaning with clear water, draining off water, removing epidermis, and mechanically pulping under aseptic condition to obtain pulp; adding purified water for dilution, performing centrifugal separation, and removing residues to obtain colloidal extract; freeze-drying the colloidal extract, spraying at low temperature, drying at 60 deg.C until the water content is 8%, cooling to room temperature, and sieving with 100-200 mesh sieve to obtain aloe extract;

the type of the chamomile extract is Camomile Distillate SB/NA 22033.

2. An anti-inflammatory product comprising the anti-inflammatory composition of claim 1 and an adjuvant.

3. An anti-inflammatory product according to claim 2, wherein the adjuvant comprises one or more of a humectant, a thickener, an emulsifier, a gelling agent, a preservative, an antioxidant, a soothing agent, a skin conditioning agent, an acid-base modifier, an emollient, a chelating agent, a fragrance, water.

4. An anti-inflammatory product according to claim 3, wherein the humectant is selected from one or more of glycerol, propylene glycol, 1, 3-butylene glycol, methyl propylene glycol, sodium hyaluronate;

the soothing agent is selected from one or more of purslane extract and alpha-bisabolol.

5. An anti-inflammatory product according to any of claims 2 to 4, wherein the anti-inflammatory product comprises an anti-inflammatory agent.

6. Use of an anti-inflammatory composition comprising claim 1 in the manufacture of a medicament having anti-inflammatory efficacy.